Actively Recruiting
Evaluating Efficacy and Safety of Anifrolumab in Chinese Adults with Active Moderate to Severe Systemic Lupus Erythematosus Over 52 Weeks
Led by AstraZeneca · Updated on 2026-10-22
417
Participants Needed
74
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of anifrolumab in Chinese adults aged 18 to 70 with active moderate to severe systemic lupus erythematosus SLE. The study aims to describe clinical outcomes focusing on remission and evaluates a systematic approach to reduce glucocorticoid GC use to minimize exposure. This phase 3b, open-label, single-arm trial collects safety, efficacy, and patient-reported outcomes in this population following current standard-of-care guidelines. Participants will receive a fixed intravenous dose of anifrolumab administered via infusion pump over at least 30 minutes every 4 weeks for a total of 13 doses from Week 0 to Week 48, alongside their stable standard treatments, which may include glucocorticoids, antimalarials, or immunosuppressants. The dosing schedule requires at least 14 days between doses, with the primary evaluation taking place at Week 52. During the study, participants will undergo regular assessments including disease activity indices, joint and skin evaluations, laboratory tests, and quality-of-life questionnaires at multiple timepoints up to Week 52. Researchers will monitor remission rates, glucocorticoid tapering success, flare rates, immune markers, and safety parameters. The total study duration for each participant is approximately one year, with detailed evaluations to understand the treatments impact on disease control and steroid reduction.
CONDITIONS
Brief Title
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here